相关实验视频
Updated: Sep 9, 2025

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
347
与肥胖相关的喘患者使用药物的成本相关障碍
Luyu Xie1, Joohan Kim2, Jaime P Almandoz3
1Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas.
Journal of managed care & specialty pharmacy
|August 30, 2025
概括
患有肥胖相关喘的人面临更高的药物成本障碍. 尽管如此,黑人和西班牙裔患有与肥胖相关的喘患者不太可能比白人患者跳过药物.
科学领域:
- 肺部医学
- 医疗服务研究
- 健康上的差异
背景情况:
- 与肥胖相关的喘 (OAA) 与健康体重的喘相比,与较差的健康结果有关.
- 成本障碍对OAA的药物坚持的影响,特别是在不同种族和族群中,仍未得到充分研究.
研究的目的:
- 研究与成本相关的药物使用障碍对OAA成年人的影响.
- 分析这些成本障碍和药物使用模式如何在种族和民族之间不同.
主要方法:
- 一项横截面研究利用了"我们所有人"计划 (2017年5月至2024年8月) 的数据.
- 通过电子健康记录确认喘和BMI≥30kg/ m2来定义与肥胖相关的喘.
- 本人报告的与成本相关的药物使用障碍是主要的结果指标.
主要成果:
- 这项研究包括21,108名成人喘患者,其中51. 7%的患者有OAA (平均BMI为38. 6kg/ m2).
- 患有OAA的患者出现与成本相关的障碍的几率更高 (aOR为1.121.31,P<0.05).
- 尽管面临负担能力问题,但非西班牙裔黑人和西班牙裔OAA个体不太可能跳过药物 (aOR分别为0.82,P=0.013;aOR为0.80,P=0.033) 和要求更低成本的替代品与非西班牙裔白人个体相比.
结论:
- 在OAA患者的成本相关障碍中发现了显著的种族和种族差异.
- 这些发现凸显了针对不同文化而定制的医疗干预措施的必要性,以缓解健康差异,并加强不同人群的喘管理.
相关概念视频
Asthma-I: Introduction
2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Asthma-III: Symptoms and Complications
2.6K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.6K
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Antiasthma Drugs: β2-Adrenoceptor Agonists
377
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
377
Inhaled Medications
388
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
388
COPD: Management Using Bronchodilators and Corticosteroids
305
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
305

